Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization
Dupilumab therapy significantly improves health-related quality of life in patients with AERD, specifically as it pertains to patient assessment of days of overall poor health and quality of life related to sinonasal and asthma symptoms.
Authors
- Kathleen M. Buchheit (ORCID: https://orcid.org/0009-0009-5134-6312)
- Rie Maurer (ORCID: https://orcid.org/0000-0003-2528-0144)
- Jillian C. Bensko (ORCID: https://orcid.org/0000-0002-0363-6093)
- Tanya M. Laidlaw (ORCID: https://orcid.org/0000-0001-6709-9795)
- Jyotsna Mullur
- Alanna McGill
- Tessa Ryan (ORCID: https://orcid.org/0009-0001-7568-4721)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Duke University (US)
Publication Details
- Journal
- American Journal of Rhinology and Allergy
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1177/19458924241298817
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.98
Funders
- Regeneron Pharmaceuticals
- National Institute of Allergy and Infectious Diseases